Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Dow
Boehringer Ingelheim
Colorcon
McKinsey

Last Updated: January 21, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202375

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 202375 describes OLMESARTAN MEDOXOMIL, which is a drug marketed by Accord Hlthcare, Alembic Pharms Ltd, Alkem Labs Ltd, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Jubilant Generics, Lupin Ltd, Macleods Pharms Ltd, Micro Labs, Mylan, Qilu, Sciegen Pharms Inc, Sunshine Lake, Teva Pharms Usa, Torrent, Umedica Labs Pvt Ltd, Zydus Pharms, Prinston Inc, and Par Pharm Inc, and is included in twenty-eight NDAs. It is available from twenty-two suppliers. Additional details are available on the OLMESARTAN MEDOXOMIL profile page.

The generic ingredient in OLMESARTAN MEDOXOMIL is amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil. There are fifty drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil profile page.
Summary for 202375
Tradename:OLMESARTAN MEDOXOMIL
Applicant:Torrent
Ingredient:olmesartan medoxomil
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 202375
Medical Subject Heading (MeSH) Categories for 202375
Suppliers and Packaging for NDA: 202375
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OLMESARTAN MEDOXOMIL olmesartan medoxomil TABLET;ORAL 202375 ANDA Torrent Pharmaceuticals Limited 13668-248 13668-248-05 500 TABLET in 1 BOTTLE (13668-248-05)
OLMESARTAN MEDOXOMIL olmesartan medoxomil TABLET;ORAL 202375 ANDA Torrent Pharmaceuticals Limited 13668-248 13668-248-30 30 TABLET in 1 BOTTLE (13668-248-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Apr 24, 2017TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Apr 24, 2017TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength40MG
Approval Date:Apr 24, 2017TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
McKinsey
Merck
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.